Webinar during PCR 2020 e-course with Dr. Antonio Colombo and Dr. Sandeep Basavarajaiah
SCBs, an appraisal on its potential advantages over paclitaxel
Is paclitaxel associated with higher mortality? The DCB in periphery conundrum: my perspective
About one year ago, a metanalysis conducted by Dr. Katsanos and Coll. showed an increase in mortality following the use of paclitaxel-coated balloons / stents when used for femoro-popliteal PTA. The whole sector was evidently shocked as a result to this metanalysis, and many actions (some of them absolutely unjustified) have been taken since then.
After one year, after a necessary cooling off period and further analyses, it is time for me to take a clear position on the matter.
Therefore, we are presenting our point of view regarding the topic, as expressed in some published editorials.
Today we are presenting the last one:
“Mortality Increase and Paclitaxil-Coated Device Use” December 2019